Nicollet Mall

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

Retrieved on: 
Venerdì, Maggio 3, 2024
Sale, Prospectus, Prader–Willi syndrome, Equity, Guggenheim Partners, PWS, Research, Nicollet Mall, Madison Avenue, Oppenheimer Holdings, Public expenditure, Form, Therapy, Tablet, Attention, Telephone, Security (finance)

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share.

Key Points: 
  • REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share.
  • The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
  • Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • Piper Sandler, Guggenheim Securities, Cantor Fitzgerald & Co. and Oppenheimer & Co. are acting as joint book-running managers for the public offering.

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Giovedì, Maggio 2, 2024
Guggenheim, Sale, Prospectus, Prader–Willi syndrome, Equity, Guggenheim Partners, PWS, Research, Nicollet Mall, Madison Avenue, Floor, Public expenditure, Form, Therapy, Tablet, Attention, Telephone, Pharmaceutical industry

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.

Key Points: 
  • REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.
  • In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering.
  • The public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The securities described above relating to the public offering are being offered by Soleno pursuant to a registration statement on Form S-3ASR (File No.

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Martedì, Aprile 16, 2024
Sale, Prospectus, Capital market, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, RBC, Suite, Security (finance), Nicollet Mall, Form, Exercise, S-3, Attention, Therapy, Telephone, SAN, Needham & Company

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Key Points: 
  • SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
  • The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $188.6 million.
  • J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated acted as joint book-running managers for the offering.
  • The public offering was made pursuant to a shelf registration statement on Form S-3 (File No.

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Retrieved on: 
Venerdì, Aprile 12, 2024
Sale, Prospectus, Capital market, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, RBC, Suite, Security (finance), Research, Nicollet Mall, Form, Attention, Therapy, Telephone, SAN, Needham & Company

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share.

Key Points: 
  • SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share.
  • The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $175.0 million.
  • Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares of common stock in connection with the public offering.
  • The offering is expected to close on or about April 16, 2024, subject to the satisfaction of customary closing conditions.

Nurix Therapeutics Announces Proposed Public Offering

Retrieved on: 
Giovedì, Aprile 11, 2024
Sale, Prospectus, Cancer, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, Suite, Security (finance), Research, Nicollet Mall, Form, Patient, Inflammation, Attention, Therapy, Telephone, SAN, Needham & Company

In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions.

Key Points: 
  • In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the proposed offering.
  • Needham & Company, LLC and RBC Capital Markets, LLC are acting as lead managers for the proposed offering.

Fulton Financial Announces Closing of $287.5 Million Offering of Common Stock

Retrieved on: 
Mercoledì, Maggio 1, 2024
Banking, Professional Services, Finance, Bank of America, Sale, Prospectus, Fulton Financial Corporation, Corporation, Republic Bank, Federal Deposit Insurance Corporation, FULT, Communication, Nicollet Mall, Form, Exercise, EDGAR, Acquisition, BofA Securities, Attention, Telephone, Security (finance)

Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the closing of its public offering of 19,166,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, which included 2,500,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Key Points: 
  • Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the closing of its public offering of 19,166,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, which included 2,500,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
  • Piper Sandler and BofA Securities acted as joint book-running managers for the offering.
  • The Corporation received net proceeds from the offering of approximately $273.5 million, after deducting underwriting discounts and before deducting transaction expenses.
  • The shares of common stock to which this communication relates were issued pursuant to an effective registration statement on Form S-3 (File No.

Fulton Financial Announces Launch of Common Stock Offering

Retrieved on: 
Lunedì, Aprile 29, 2024
Banking, Professional Services, Bank of America, Sale, Prospectus, Fulton Financial Corporation, Corporation, Republic Bank, Federal Deposit Insurance Corporation, FULT, Communication, Nicollet Mall, Form, EDGAR, Acquisition, BofA Securities, Attention, Telephone, Security (finance)

Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced that it commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced that it commenced an underwritten public offering of shares of its common stock.
  • The Corporation expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.
  • Piper Sandler and BofA Securities are acting as joint book-running managers for the offering.
  • The offering is being made only by means of a prospectus supplement and accompanying base prospectus.

Fulton Financial Announces Pricing of $250 Million Offering of Common Stock

Retrieved on: 
Lunedì, Aprile 29, 2024
Banking, Professional Services, Finance, Bank of America, Sale, Prospectus, Fulton Financial Corporation, Corporation, Republic Bank, Federal Deposit Insurance Corporation, FULT, Communication, Nicollet Mall, Form, EDGAR, Acquisition, BofA Securities, Attention, Telephone, Security (finance)

Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the pricing of its public offering of 16,666,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, for an aggregate offering amount of $250 million.

Key Points: 
  • Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the pricing of its public offering of 16,666,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, for an aggregate offering amount of $250 million.
  • In addition, the Corporation has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock at the public offering price, less underwriting discounts.
  • Piper Sandler and BofA Securities acted as joint book-running managers for the offering.
  • The offering is being made only by means of a prospectus supplement and accompanying base prospectus.

UMB Financial Corporation Announces Pricing of an Underwritten Offering of 2,800,000 Shares of Common Stock

Retrieved on: 
Lunedì, Aprile 29, 2024
Banking, Professional Services, Finance, Bank of America, UMBF, Sale, Prospectus, RBC Capital Markets, UMB Financial Corporation, Vesey Street, Security (finance), Nicollet Mall, Form, Exercise, Varick Street, Morgan Stanley, 2nd Floor, Wellington Management Company, BofA Securities, S-3, UMB, Attention, Telephone

The underwriters have been granted the option to purchase up to an additional 420,000 shares of UMB’s common stock.

Key Points: 
  • The underwriters have been granted the option to purchase up to an additional 420,000 shares of UMB’s common stock.
  • Such borrowed shares of UMB’s common stock will be delivered by BofA Securities (in such capacity, the “forward seller”) for sale to the underwriters in the offering.
  • UMB will not receive any proceeds from the sale of the shares of its common stock sold by the forward seller to the underwriters.
  • The offering of these securities may be made only by means of a prospectus supplement and accompanying base prospectus relating to this offering.

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Retrieved on: 
Giovedì, Marzo 28, 2024
Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.
  • All shares and pre-funded warrants in the offering are being offered by Praxis.
  • In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.